New combo shows promise for tough bile duct cancer
NCT ID NCT04550624
First seen Feb 01, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 27 people with advanced bile duct cancer that had stopped responding to standard treatments. The goal was to see if the combination could shrink tumors and control the disease. This is not a cure, but aims to manage the cancer and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Jiahui International Hospital
Shanghai, Shanghai Municipality, 200233, China
-
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, 200233, China
Conditions
Explore the condition pages connected to this study.